摘要
目的:应用LC-MS/MS蛋白质组学方法研究维脑康胶囊治疗大鼠局灶性脑缺血再灌注损伤的作用机制。方法:大鼠分为正常对照组、模型对照组及维脑康胶囊组,取大鼠全血离心获得血清,进行酶解,应用nano Chip-ESI Ion Trap进行样本分析,测定结果利用Agilent Spectral mill、scaffold及SIMCA P+等软件进行蛋白鉴定、模式判别及蛋白相对定量分析。结果:最终比对出正常对照组、模型对照组和维脑康胶囊组的总蛋白数分别为833个、701个和798个,与正常对照组相比,模型对照组分析出的差异蛋白共18个,其中上调的是13个蛋白,下调的是5个蛋白,而在维脑康胶囊组中这些差异蛋白的表达均有所恢复,其功能分别与神经元凋亡、神经元生长与分化、信号通路及转录调控等过程密切相关。结论:维脑康胶囊治疗局灶性脑缺血再灌注的作用机制可能与这些差异蛋白有关,为维脑康胶囊作用的分子机制研究提供了新思路。
Objective: To investigate the molecule mechanism of Weinaokang in treatment of the rats with focal cerebral ischemia reperfusion by using LC-MSMS method. Methods: Global proteomics analysis had been conducted on serum samples collected from normal group,model group,and Weinaokang treatment group. After digestion,the samples were detected by applying nano Chip-ESI Ion Trap.Protein identification,pattern discrimination and relative quantitative analysis were determined using Agilent Spectral mill、scaffold 3 and SIMCA P + software. Results: 833,701 and 798 proteins were found on healthy group,model group,and TCM treatment group respectively. Compared with healthy group,18 changed proteins had been determined: 13 proteins up-regulated,5 proteins down-regulated in model group,and these differential proteins had converse tendency in TCM treatment group. Current studies also aim at the major functional classification of proteins between model and health groups,as well as model and treatment groups. The biological function of these changed proteins were closely related to growth and differentiation of neurons,neuronal apoptosis,signal transduction and regulation of translation,etc. Conclusion: The molecule mechanism of Weinaokang capsule for treating focal cerebral ischemia reperfusion may be associated with different proteins,and it will provide a new idea for study of molecule mechanism of Weinaokang capsule.
出处
《世界中医药》
CAS
2013年第10期1137-1141,1146,共6页
World Chinese Medicine
基金
科技部十二五重大新药创制课题(编号:2012ZX09301002-004)
科技部国际合作项目(编号:2011DFA31440)
北京市"十病十药"研发(编号:Z121102001112006)